Association of osteopontin and cyclooxygenase‑2 expression with breast cancer subtypes and their use as potential biomarkers

Thorat,Dhanashri; Sahu,Asutosh; Behera,Reeti; Lohite,Kirti; Deshmukh,Sanjay; Mane,Anupama; Karnik,Swapnil; Doke,Suhaschandra; Kundu,Gopal  C.

doi:10.3892/ol.2013.1600

Association of osteopontin and cyclooxygenase‑2 expression with breast cancer subtypes and their use as potential biomarkers

Authors:
- Dhanashri Thorat
- Asutosh Sahu
- Reeti Behera
- Kirti Lohite
- Sanjay Deshmukh
- Anupama Mane
- Swapnil Karnik
- Suhaschandra Doke
- Gopal C. Kundu
View Affiliations

Affiliations: Department of Tumor Biology, Angiogenesis and Nanomedicine, National Centre for Cell Science, Pune, Maharashtra 411007, India, Grant Medical Foundation, Ruby Hall Clinic, Pune, Maharashtra 411001, India, Institute for Advanced Computing and Life Sciences, Pune, Maharashtra 411004, India
Published online on: October 1, 2013 https://doi.org/10.3892/ol.2013.1600
Pages: 1559-1564

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is one of the most common malignant tumors among females worldwide and remains a leading cause of cancer‑related mortality. Due to the heterogeneous clinical nature of breast cancer, it is necessary to identify new biomarkers that are associated with tumor growth, angiogenesis and metastasis. Osteopontin (OPN) and cyclooxygenase‑2 (COX‑2) are known to be overexpressed in invasive breast cancer and their overexpression is associated with aggressive histological and clinical features. The present study assessed OPN and COX‑2 expression in various subtypes of breast cancer. The expression of OPN and COX‑2 was analyzed using immunohistochemistry (IHC) in a cohort of 67 invasive ductal breast carcinoma patients. The statistical analysis was performed using standard statistical software SPSS version 18.0. The associations between OPN and COX‑2 and the human epidermal growth factor receptor type 2 (HER2)‑overexpressing and non‑HER2‑overexpressing subtypes were evaluated using the Mann‑Whitney U test. The mean OPN level was significantly higher in the HER2‑overexpressing subtype compared with the non‑HER2‑overexpressing subtype. Furthermore, the mean COX‑2 expression levels were higher in the HER2‑overexpressing subtype compared with the luminal A, luminal B or triple‑negative groups. It is well known that carcinomas overexpressing HER2/neu have a worse prognosis than luminal tumors. Hence, it may be hypothesized that an elevated expression of OPN and COX‑2 in a HER2‑overexpressing subtype may contribute to a more aggressive behavior and be used as diagnostic and prognostic markers in breast cancer.

View Figures

View References

1	Murthy NS, Chaudhry K, Nadayil D, Agarwal UK and Saxena S: Changing trends in incidence of breast cancer: Indian scenario. Indian J Cancer. 46:73–74. 2009. View Article : Google Scholar : PubMed/NCBI
2	Sengupta A: The emergence of the menopause in India. Climacteric. 6:92–95. 2003. View Article : Google Scholar : PubMed/NCBI
3	Kapur P, Sinha B and Pereira BM: Measuring climacteric symptoms and age at natural menopause in an Indian population using the Greene Climacteric Scale. Menopause. 16:378–384. 2009. View Article : Google Scholar : PubMed/NCBI
4	Rangaswami H, Bulbule A and Kundu GC: Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 16:79–87. 2006. View Article : Google Scholar : PubMed/NCBI
5	Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM and Hogan BL: Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest. 101:1468–1478. 1998. View Article : Google Scholar : PubMed/NCBI
6	Sodek J, Ganss B and McKee MD: Osteopontin. Crit Rev Oral Biol Med. 11:279–303. 2000. View Article : Google Scholar
7	Jain S, Chakraborty G, Bulbule A, Kaur R and Kundu GC: Osteopontin: an emerging therapeutic target for anticancer therapy. Expert Opin Ther Targets. 11:81–90. 2007. View Article : Google Scholar : PubMed/NCBI
8	Ahmed M, Behera R, Chakraborty G, et al: Osteopontin: a potentially important therapeutic target in cancer. Expert Opin Ther Targets. 15:1113–1126. 2011. View Article : Google Scholar : PubMed/NCBI
9	Rudland PS, Platt-Higgins A, El-Tanani M, et al: Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res. 62:3417–3427. 2002.PubMed/NCBI
10	Chakraborty G, Jain S, Behera R, Ahmed M, Sharma P, Kumar V and Kundu GC: The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med. 6:819–830. 2006. View Article : Google Scholar : PubMed/NCBI
11	Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B and Weber GF: Osteopontin-c is a selective marker for breast cancer. Int J Cancer. 122:889–897. 2008. View Article : Google Scholar : PubMed/NCBI
12	Henry NL and Hayes DF: Uses and abuses of tumor markers in the diagnosis, monitoring and treatment of primary and metastatic breast cancer. Oncologist. 11:541–552. 2006. View Article : Google Scholar : PubMed/NCBI
13	Clark GM: Prognostic and predictive factors. Diseases of the Breast. Harris JR, Lippman ME, Morrow M and Osborne CK: Lippinscott, Williams and Wilkins; Philadelphia: pp. 489–514. 2000
14	Andre F and Pusztai L: Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. Nat Clin Pract Oncol. 3:621–632. 2006. View Article : Google Scholar : PubMed/NCBI
15	Chandrasekharan NV and Simmons DL: The cyclooxygenases. Genome Biol. 5:2412004. View Article : Google Scholar : PubMed/NCBI
16	Ramsay RG, Ciznadija D, Vanevski M and Mantamadiotis T: Transcriptional regulation of cyclo-oxygenase expression: three pillars of control. Int J Immunopathol Pharmacol. 16:S59–S67. 2003.PubMed/NCBI
17	Sarkar FH, Adsule S, Li Y and Padhye S: Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy. Mini Rev Med Chem. 7:599–608. 2007. View Article : Google Scholar : PubMed/NCBI
18	Kis B, Snipes JA, Isse T, Nagy K and Busija DW: Putative cyclooxygenase-3 expression in rat brain cells. J Cereb Blood Flow Metab. 23:1287–1292. 2003. View Article : Google Scholar : PubMed/NCBI
19	Ristimäki A, Sivula A, Lundin J, et al: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 62:632–635. 2002.PubMed/NCBI
20	Boland GP, Butt IS, Prasad R, Knox WF and Bundred NJ: COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer. 90:423–429. 2004. View Article : Google Scholar : PubMed/NCBI
21	Shim V, Gauthier ML, Sudilovsky D, et al: Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium. Cancer Res. 63:2347–2350. 2003.PubMed/NCBI
22	Costa C, Soares R, Reis-Filho JS, Leitão D, Amendoeira I and Schmitt FC: Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol. 55:429–434. 2002. View Article : Google Scholar : PubMed/NCBI
23	Davies G, Salter J, Hills M, Martin LA, Sacks N and Dowsett M: Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin Cancer Res. 9:2651–2656. 2003.PubMed/NCBI
24	Denkert C, Winzer KJ, Müller BM, et al: Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer. 97:2978–2987. 2003. View Article : Google Scholar : PubMed/NCBI
25	Shim JY, An HJ, Lee YH, Kim SK, Lee KP and Lee KS: Overexpression of cyclooxygenase-2 is associated with breast carcinoma and its poor prognostic factors. Mod Pathol. 16:1199–1204. 2003. View Article : Google Scholar : PubMed/NCBI
26	Tan KB, Yong WP and Putti TC: Cyclooxygenase-2 expression: a potential prognostic and predictive marker for high-grade ductal carcinoma in situ of the breast. Histopathology. 44:24–28. 2004. View Article : Google Scholar : PubMed/NCBI
27	Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F and Brunet M: Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer. 64:1914–1921. 1989.
28	Greene FL, Page DL and Fleming ID: AJCC Cancer Staging Manual. 6th edition. Springer; New York, NY: 2002, View Article : Google Scholar
29	Allred DC, Clark GM, Elledge R, et al: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 85:200–206. 1993. View Article : Google Scholar : PubMed/NCBI
30	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
31	Glass AG, Lacey JV Jr, Carreon JD and Hoover RN: Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst. 99:1152–1161. 2007.
32	Ravdin PM, Cronin KA, Howlader N, et al: The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 356:1670–1674. 2007. View Article : Google Scholar : PubMed/NCBI
33	Carey LA, Perou CM, Livasy CA, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar : PubMed/NCBI
34	Dolled-Filhart M, Rydén L, Cregger M, Jirstrom K, Harigopal M, Camp RL and Rimm DL: Classification of breast cancer using genetic algorithms and tissue microarrays. Clin Cancer Res. 12:6459–6468. 2006. View Article : Google Scholar : PubMed/NCBI
35	Liu R, Wang X, Chen GY, et al: The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med. 356:217–226. 2007. View Article : Google Scholar : PubMed/NCBI
36	Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 100:8418–8423. 2003. View Article : Google Scholar : PubMed/NCBI
37	Sørlie T, Perou CM, Fan C, et al: Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther. 5:2914–2918. 2006.
38	Van de Vijver MJ, He YD, van’t Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 347:1999–2009. 2002.
39	Wang Y, Klijn JG, Zhang Y, et al: Gene expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 365:671–679. 2005. View Article : Google Scholar : PubMed/NCBI
40	Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H and van de Vijver MJ: Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 9:R652007. View Article : Google Scholar : PubMed/NCBI
41	Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
42	Tsuda H, Hirohashi S, Shimosato Y, et al: Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res. 49:3104–3108. 1989.PubMed/NCBI